GLP-3(R) is a synthetic research peptide classified as a triple hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. This triple receptor mechanism distinguishes GLP-3(R) from earlier single or dual agonist compounds and has made it a subject of significant interest in metabolic research.
How It Works
GLP-3(R) engages three separate receptor pathways at once. GLP-1 and GIP receptor activation supports increased insulin secretion, increased glucose uptake, increased satiety, and decreased rate of gastric emptying. The addition of glucagon receptor activity introduces a third pathway — increasing energy expenditure and lipolysis, decreasing lipogenesis, and increasing insulin secretion. Together these three pathways work in parallel rather than in sequence, which is what separates triple agonists from earlier generation compounds in this research category.
Where the Research Stands
GLP-3(R) has been the subject of Phase 2 and Phase 3 clinical investigation. A 2023 Phase 2 trial published in the New England Journal of Medicine found substantial reductions in body weight after 48 weeks, with higher doses associated with weight reductions exceeding 24%. Phase 3 trials are ongoing with multiple readouts expected through 2026.
GLP-3(R) research has also expanded beyond metabolic outcomes. Researchers are examining its role in hepatic fat reduction, cardiovascular risk markers, and energy homeostasis regulation. Its triple receptor profile makes it a valuable tool for studying how simultaneous multi-receptor engagement differs from sequential or single-pathway activation in controlled experimental settings.
About GLP-3(R) Research
As a triple receptor agonist, GLP-3(R) represents a more complex pharmacological profile than GLP-1 single agonists or dual agonists. Researchers using GLP-3(R) should design experiments that account for the overlapping downstream effects of simultaneous GLP-1, GIP, and glucagon receptor activation. Full compound specifications and COA documentation are available upon request from Alpha Tides.
Product Details
- Form: Lyophilized powder
- Size: 30mg per vial
- Purity: 99% | COA available on request
- Storage: Keep dry and away from light before reconstitution. Refrigerate after reconstitution.
Research Use Only
GLP-3(R) is intended strictly for laboratory research by qualified professionals. It is not FDA approved and is not for human or animal use. By purchasing, the buyer confirms the product will be used solely for in vitro research in compliance with all applicable laws and regulations.
Reviews
There are no reviews yet.